Log inSign up
AAOIFI No. 21 screening

Is ZYME halal?

Zymeworks Inc.

Not halal

Zymeworks Inc. did not pass AAOIFI screening. The failed check is shown below.

Checked: 15 October 2026

Exchange

NASDAQ

Price

25.03

Day

-2.80%

Market cap

$1.86B

Industry

Biotechnology

Sector

Healthcare

What the company does

Zymeworks (Canada/US) is an oncology biotech whose drug Ziihera (zanidatamab, for HER2 biliary tract cancer) is sold by Jazz Pharmaceuticals; other candidates are in trials. Money comes from royalties, milestone payments and licensing.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $1.16B = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $322.48M ÷ 36-month average market cap $1.16B = 27.8%

    27.8%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    Interest income $13.35M ÷ annual revenue $105.97M (2025) = 12.6%

    12.6%

    Fail

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $1.86B.

For information (AAOIFI 3/1 note): cash + receivables are 69.7% of total assets (2026-06-30). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyZYME's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →